A detailed history of Black Rock Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 7,782,517 shares of EDIT stock, worth $9.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,782,517
Previous 7,832,781 0.64%
Holding current value
$9.73 Million
Previous $58.1 Million 37.47%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$4.67 - $7.28 $234,732 - $365,921
-50,264 Reduced 0.64%
7,782,517 $36.3 Million
Q1 2024

May 10, 2024

SELL
$7.03 - $11.07 $43,501 - $68,501
-6,188 Reduced 0.08%
7,832,781 $58.1 Million
Q4 2023

Feb 13, 2024

SELL
$6.25 - $11.11 $2.01 Million - $3.57 Million
-321,064 Reduced 3.93%
7,838,969 $79.4 Million
Q3 2023

Nov 13, 2023

BUY
$6.92 - $9.31 $3.91 Million - $5.25 Million
564,337 Added 7.43%
8,160,033 $63.6 Million
Q2 2023

Aug 11, 2023

BUY
$6.36 - $11.47 $1.13 Million - $2.03 Million
177,334 Added 2.39%
7,595,696 $62.5 Million
Q1 2023

May 12, 2023

BUY
$7.03 - $11.53 $559,728 - $918,018
79,620 Added 1.08%
7,418,362 $53.8 Million
Q4 2022

Feb 13, 2023

BUY
$8.32 - $13.21 $2.96 Million - $4.7 Million
355,967 Added 5.1%
7,338,742 $65.1 Million
Q3 2022

Nov 14, 2022

BUY
$12.16 - $19.42 $3.14 Million - $5.02 Million
258,565 Added 3.85%
6,982,775 $85.5 Million
Q2 2022

Aug 12, 2022

BUY
$9.99 - $21.35 $4.48 Million - $9.58 Million
448,940 Added 7.15%
6,724,210 $79.5 Million
Q1 2022

May 12, 2022

BUY
$14.08 - $27.63 $11.9 Million - $23.3 Million
841,894 Added 15.49%
6,275,270 $119 Million
Q4 2021

Feb 10, 2022

SELL
$26.55 - $40.57 $282,332 - $431,421
-10,634 Reduced 0.2%
5,433,376 $144 Million
Q3 2021

Nov 09, 2021

SELL
$39.27 - $72.94 $5.54 Million - $10.3 Million
-141,179 Reduced 2.53%
5,444,010 $224 Million
Q2 2021

Aug 11, 2021

BUY
$31.29 - $56.64 $175 Million - $316 Million
5,585,189 New
5,585,189 $316 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $85.9M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.